Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
WELLCOVORIN vs HUMATIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Folinic acid (leucovorin) is a reduced form of folic acid that bypasses dihydrofolate reductase inhibition, providing cofactors for nucleotide synthesis and reversing the effects of folate antagonists such as methotrexate.
Aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of m RNA and production of nonfunctional proteins.
Rescue therapy after high-dose methotrexate therapy in osteosarcoma,Treatment of advanced colorectal cancer in combination with fluorouracil (off-label),To diminish toxicity and counteract effects of folic acid antagonists (e.g., trimethoprim, pyrimethamine) in certain infections
Hepatic coma (adjunctive therapy to reduce ammonia-forming bacteria in the gut),Diarrhea caused by enteropathogenic bacteria (e.g., Shigella, E. coli, Salmonella, Proteus, Staphylococcus, Pseudomonas aeruginosa)
WELLCOVORIN (levoleucovorin) is administered intravenously or intramuscularly at a dose of 7.5 mg (approximately 0.1 mg/kg) every 6 hours for 10 doses starting 24 hours after the end of methotrexate infusion. Alternatively, 15 mg orally every 6 hours for 10 doses, starting 24 hours after methotrexate infusion.
15-25 mg/kg/day orally in 4 divided doses for hepatic coma; 50 mg/kg/day orally in 4 divided doses for infectious diarrhea, max 4 g/day.
The terminal elimination half-life of folinic acid (active reduced folate) is approximately 6-7 hours in patients with normal renal function. The pharmacologically active metabolite, 5-methyltetrahydrofolate, has a longer half-life of about 10-12 hours. In renal impairment, half-life may be prolonged.
2-3 hours (serum half-life of absorbed fraction); clinically negligible due to minimal systemic absorption
Folinic acid is metabolized via reduction and methylation to active folate forms (e.g., 5-methyltetrahydrofolate) in the liver and other tissues. Involves dihydrofolate reductase and other folate-metabolizing enzymes.
Minimally absorbed from the gastrointestinal tract; systemically absorbed drug undergoes minimal hepatic metabolism.
Primarily renal excretion as unchanged drug and metabolites; about 80-90% of a dose is excreted in urine within 24 hours, with approximately 50-70% as unchanged folinic acid and the remainder as 5-methyltetrahydrofolate and other metabolites. Fecal excretion accounts for <10%.
Primarily unchanged in feces (~90%); small amount absorbed is excreted renally as unchanged drug (~1%)
Approximately 15% bound to plasma proteins, mainly albumin. Binding is not extensive.
0% (negligible binding due to high polarity and minimal absorption)
Volume of distribution is approximately 0.5-0.6 L/kg, indicating distribution into total body water and some tissue binding. It crosses the blood-brain barrier poorly.
0.2 L/kg (reflects limited distribution to extracellular fluid in absorbed fraction; primarily confined to GI tract)
Oral bioavailability is variable: approximately 25-30% for the active isomer (l-folinic acid) due to first-pass metabolism; the racemic mixture (d,l-folinic acid) has a lower absolute bioavailability of about 30% for the active component. Intravenous and intramuscular routes provide 100% bioavailability.
Oral: ~1% (ranges 0.5-1.5% due to poor absorption from gastrointestinal tract)
No specific GFR-based dose modifications are provided in the prescribing information. However, levoleucovorin is renally eliminated, and caution is advised in patients with renal impairment. For severe renal impairment (Cr Cl < 10 m L/min), consider dose reduction or extended interval. Monitor methotrexate levels and adjust leucovorin dose accordingly.
Reduce dose and/or extend interval based on Cr Cl: Cr Cl 50-90 m L/min: 60-90% of dose; Cr Cl 10-50 m L/min: 30-60% of dose; Cr Cl <10 m L/min: 20-30% of dose.
No specific dose adjustments are recommended for hepatic impairment based on Child-Pugh class. However, caution is advised in patients with significant hepatic dysfunction due to potential altered folate metabolism.
No specific Child-Pugh based adjustments; caution in severe hepatic impairment due to potential nephrotoxicity.
WELLCOVORIN is not FDA approved for pediatric use. However, in pediatric patients, levoleucovorin is sometimes used at a dose of 10 mg/m² (or 0.2 mg/kg) every 6 hours for 5-7 doses, starting 24 hours after methotrexate infusion, adjusted based on methotrexate levels. Dosing should be individualized based on clinical response and methotrexate concentration.
For hepatic coma: 15-25 mg/kg/day orally in 4 divided doses; for infectious diarrhea: 50 mg/kg/day orally in 4 divided doses, max 4 g/day.
No specific geriatric dose adjustments are recommended. Due to age-related decline in renal function, monitor renal function and methotrexate levels closely, and consider dose adjustment based on creatinine clearance.
Adjust based on renal function; monitor for nephrotoxicity and ototoxicity; consider lower initial doses due to age-related renal decline.
No FDA black box warning.
No FDA black box warning.
May mask pernicious anemia and other megaloblastic anemias due to vitamin B12 deficiency; caution in patients with renal impairment; hypersensitivity reactions; gastrointestinal toxicity with 5-FU combination.
Ototoxicity (mainly with prolonged use or renal impairment),Nephrotoxicity,Neuromuscular blockade (use caution in patients with myasthenia gravis or receiving neuromuscular blocking agents),Superinfection with resistant organisms,Use in renal impairment may increase risk of toxicity,Not for systemic infections (poor absorption)
History of severe hypersensitivity to folinic acid; pernicious anemia or other megaloblastic anemias secondary to vitamin B12 deficiency.
Hypersensitivity to paromomycin or other aminoglycosides,Intestinal obstruction,Severe ulcerative bowel lesions
No significant food interactions have been reported. However, maintain adequate hydration and avoid alcohol due to potential hepatotoxicity. No specific dietary restrictions are required.
No significant food interactions. Administer with meals to minimize gastrointestinal irritation.
WELLCOVORIN (levoleucovorin) is a folate analog. Folate is essential for fetal development. Wellcovorin is the active enantiomer of leucovorin, which is used to counteract folic acid antagonists. Available data do not indicate an increased risk of major birth defects with therapeutic doses. However, high-dose methotrexate therapy (which Wellcovorin is used to rescue from) is teratogenic. During first trimester, folate supplementation is protective against neural tube defects. During second and third trimester, folate requirements increase. No specific fetal risks are known from Wellcovorin alone. However, the underlying condition requiring treatment may pose risks.
FDA Pregnancy Category D. Humatin (paromomycin) is an aminoglycoside antibiotic. There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans. However, potential benefits may warrant use in pregnant women despite potential risks. Aminoglycosides can cause fetal harm when administered to a pregnant woman, including ototoxicity and nephrotoxicity. Paromomycin is poorly absorbed after oral administration, so systemic exposure is minimal. Risk is considered low, but caution is advised.
Levoleucovorin is excreted into human milk. The M/P ratio is not established. Due to low molecular weight, excretion is expected. Exposure to the breastfed infant is likely low. Caution is advised. Use only if clearly needed.
It is not known whether paromomycin is excreted in human milk after oral administration. Paromomycin is minimally absorbed systemically, so exposure to breastfed infants is expected to be low. However, because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. M/P ratio: Not available.
Pregnancy increases folate clearance. Dose may need adjustment to maintain adequate serum folate levels, especially in high-dose methotrexate rescue. Monitor serum folate and adjust dose accordingly. Specific dose changes are not established; clinical judgment and monitoring are required.
No dose adjustment is required during pregnancy. Paromomycin is poorly absorbed orally, and its pharmacokinetics are not significantly altered in pregnancy. However, caution is advised in patients with renal impairment or inflammatory bowel disease due to potential increased absorption.
WELLCOVORIN (levoleucovorin) is the active l-isomer of leucovorin; it does not require metabolic activation and is preferred in patients with dihydropyrimidine dehydrogenase (DPD) deficiency. It is used to reduce the toxicity of methotrexate (MTX) and to enhance the efficacy of fluorouracil (5-FU). When used for MTX rescue, initiate 24 hours after start of MTX infusion; monitor serum MTX levels, creatinine, and urine p H. Rescue dose and duration depend on MTX levels; continue until MTX level < 0.05 μmol/L. For 5-FU modulation, administer immediately before or simultaneously with 5-FU; do not use with irinotecan due to increased diarrhea risk.
Humatin (paromomycin) is an aminoglycoside antibiotic used primarily for intestinal amebiasis and hepatic coma. For hepatic coma, use as short-term adjunctive therapy; monitor for ototoxicity and nephrotoxicity, especially in renal impairment. Oral absorption is poor, so systemic toxicity is rare except with ulcerative bowel disease. Administer with food to reduce GI upset.
Take this medication exactly as prescribed; do not change the dose or frequency without consulting your doctor.,This drug may be given as an injection or as an oral tablet; follow the instructions for the specific formulation you receive.,If you miss a dose, contact your healthcare provider; do not double the next dose.,Report any signs of allergic reaction (rash, hives, swelling, difficulty breathing) or severe gastrointestinal symptoms (severe diarrhea, vomiting, abdominal pain) immediately.,Drink plenty of fluids to stay hydrated, especially during chemotherapy treatment.,Avoid alcohol while taking this medication as it may increase the risk of liver toxicity.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
Take this medication exactly as prescribed, with food to lessen stomach upset.,Complete the full course of therapy even if you feel better.,Drink plenty of fluids to maintain hydration.,Report any hearing loss, ringing in ears, dizziness, or changes in urine output immediately.,May cause diarrhea; notify your doctor if severe or persistent.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about WELLCOVORIN vs HUMATIN, answered by our medical review team.
WELLCOVORIN is a Folic Acid Derivative that works by Folinic acid (leucovorin) is a reduced form of folic acid that bypasses dihydrofolate reductase inhibition, providing cofactors for nucleotide synthesis and reversing the effects of folate antagonists such as methotrexate.. HUMATIN is a Aminoglycoside Antibiotic that works by Aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of m RNA and production of nonfunctional proteins.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between WELLCOVORIN and HUMATIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of WELLCOVORIN is: WELLCOVORIN (levoleucovorin) is administered intravenously or intramuscularly at a dose of 7.5 mg (approximately 0.1 mg/kg) every 6 hours for 10 doses starting 24 hours after the end of methotrexate infusion. Alternatively, 15 mg orally every 6 hours for 10 doses, starting 24 hours after methotrexate infusion.. The standard adult dose of HUMATIN is: 15-25 mg/kg/day orally in 4 divided doses for hepatic coma; 50 mg/kg/day orally in 4 divided doses for infectious diarrhea, max 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between WELLCOVORIN and HUMATIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. WELLCOVORIN is classified as Category C. WELLCOVORIN (levoleucovorin) is a folate analog. Folate is essential for fetal development. Wellcovorin is the active enantiomer of leucovorin, which is used to counteract folic ac. HUMATIN is classified as Category C. FDA Pregnancy Category D. Humatin (paromomycin) is an aminoglycoside antibiotic. There is positive evidence of human fetal risk based on adverse reaction data from investigational . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.